Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Elder

Facial Plastic Surgery Lewes, DE Doctor of Osteopathy

NPI 1821223413 CMS profile 614439

17005 Old Orchard Rd, Lewes, DE 19958

Open in the dashboard

General payments

$1,535

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Elder of Lewes, DE is reported in the CMS Open Payments database as having received $1,535 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $114 4
2024 General $250 8
2023 General $377 15
2022 General $410 8
2021 General $65 2
2020 General $211 4
2019 General $108 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Elder
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Justin Elder were reported at $114. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Justin Elder Facial Plastic Surgery median Middle half National median
2019 $108 $225 $92–$651 $163
2020 $211 $132 $45–$323 $114
2021 $65 $186 $67–$558 $132
2022 $410 $218 $83–$594 $149
2023 $377 $237 $94–$564 $160
2024 $250 $233 $104–$575 $164
2025 $114 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurent Medical Limited $393 13 payments
  2. Aerin Medical Inc. $338 6 payments
  3. Regeneron Healthcare Solutions, Inc. $164 8 payments
  4. Horizon Therapeutics plc $97 1 payment
  5. Inspire Medical Systems, Inc. $93 2 payments
  6. Baxter Healthcare $76 1 payment
  7. Acclarent, Inc $68 3 payments
  8. AxoGen $67 1 payment
  9. Medtronic, Inc. $66 2 payments
  10. Genzyme Corporation $40 2 payments
  11. Other $134 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,459 46 payments
  2. Debt forgiveness $76 1 payment
Products named General payments · program years 2019–2025
  1. NEUROMARK Radiofrequency Console $393 13 payments
  2. NEUROMARK Device $393 13 payments
  3. DUPIXENT $136 7 payments
  4. VIVAER STYLUS $131 4 payments
  5. RHINAER STYLUS $131 4 payments
  6. TEPEZZA $97 1 payment
  7. INSPIRE $93 2 payments
  8. Avance Nerve Graft $67 1 payment
  9. AxoGuard Nerve Connector $67 1 payment
  10. AXOGUARD NERVE PROTECTOR $67 1 payment
  11. Other $355 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,618

Median for Otolaryngology: 297

Drug cost

$52,550

Median for Otolaryngology: $6,314

Branded share of claims

7.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine-Fluticasone Azelastine/Fluticasone Brand 55 $13,386
Ipratropium Bromide Generic 226 $10,825
Fluticasone Propionate Generic 217 $4,757
Montelukast Sodium Generic 204 $4,373
Levocetirizine Dihydrochloride Generic 162 $4,308
Azelastine Hcl Generic 70 $2,880
Mometasone Furoate Generic 25 $2,573
Omeprazole Generic 72 $1,509
Famotidine Generic 110 $1,440
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 12 $1,135

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$488,092

Medicare's payments for the services billed

Medicare patients

1,736

Average age 75

Services billed

12,215

914 women, 822 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 39%
Diabetes 24%
Depression 20%
Chronic kidney disease 19%
COPD 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record